The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Mironova Yu.S.
Siberian State Medical University, Tomsk, Russia
Zhukova N.G.
Siberian State Medical University, Tomsk, Russia
Zhukova I.A.
Siberian State Medical University, Tomsk
Alifirova V.M.
Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia
Izhboldina O.P.
Siberian State Medical University, Tomsk
Latypova A.V.
Siberian State Medical University, Tomsk, Russia
Parkinson’s disease and glutamatergic system
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(5): 138‑142
Views: 4922
Downloaded: 128
To cite this article:
Mironova YuS, Zhukova NG, Zhukova IA, Alifirova VM, Izhboldina OP, Latypova AV. Parkinson’s disease and glutamatergic system. S.S. Korsakov Journal of Neurology and Psychiatry.
2018;118(5):138‑142. (In Russ.)
https://doi.org/10.17116/jnevro201811851138
Clinical variants of Parkinson’s disease (PD) are not restricted to motor symptoms but include a wide spectrum of different non-motor symptoms: cognitive, psychotic, autonomic and sensory. These non-motor symptoms often occur long before classical motor features. Associated pathologic changes can now be identified at earliest stages using neuroimaging, pathomorphological and genetic studies. Therefore, PD is currently considered as a multifactorial, heterogenic systemic disease associated with involvement of multiple neurotransmitter systems. This leads to understanding that not only dopaminergic but also other neurotransmitter systems, including glutamatergic system, are involved in the pathogenesis of PD. This article aimed at investigating a role of glutamatergic system in the initiation of neurodegenerative process. The role of glutamate as a neurotransmitter and a neurotoxin in the pathogenesis of PD and progression of its clinical manifestations is discussed. The authors suggest that research into glutamate excitotoxicity in PD patients might allow the improvement of treatment tactics and correction of pathogenetic therapy.
Keywords:
Authors:
Mironova Yu.S.
Siberian State Medical University, Tomsk, Russia
Zhukova N.G.
Siberian State Medical University, Tomsk, Russia
Zhukova I.A.
Siberian State Medical University, Tomsk
Alifirova V.M.
Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk, Russia
Izhboldina O.P.
Siberian State Medical University, Tomsk
Latypova A.V.
Siberian State Medical University, Tomsk, Russia
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.